Still no evidence for the efficacy of zuranolone beyond two weeks: Response to Arnaud and Bonthapally
- PMID: 35780962
- DOI: 10.1016/j.jad.2022.06.085
Still no evidence for the efficacy of zuranolone beyond two weeks: Response to Arnaud and Bonthapally
Comment on
-
Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder.J Affect Disord. 2021 Apr 15;285:112-119. doi: 10.1016/j.jad.2021.02.027. Epub 2021 Feb 10. J Affect Disord. 2021. PMID: 33640861
-
Non-superiority of zuranolone (SAGE-217) at the longer-term.J Affect Disord. 2021 Aug 1;291:329-330. doi: 10.1016/j.jad.2021.05.015. Epub 2021 May 23. J Affect Disord. 2021. PMID: 34082218 No abstract available.
-
Zuranolone provides a rapid response without chronic dosing: Response to correspondence by ten Doesschate et al.J Affect Disord. 2022 Mar 15;301:445-447. doi: 10.1016/j.jad.2022.01.059. Epub 2022 Jan 13. J Affect Disord. 2022. PMID: 35032505 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
